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Abstract 
The applications of the tetracycline class of antibiotics extend beyond their antimicrobial activity 
to anti-inflammatory, immunosuppressive and neuroprotective applications, making it a 
commonly used class of medication. Minocycline, a second-generation tetracycline, has inherent 
characteristics that improve absorption and distribution. These benefits promote even more 
widespread use. This familiarity of usage breeds prescriptive complacency toward the 
dermatologic complications including hyperpigmentation. The following case explores these 
adverse manifestations of minocycline use. 
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Introduction 
Since the 1950s, the broad-spectrum antibiotic tetracycline, a polyketide from the Streptomyces 
genus of Actinobacter,1 has commonly been used to treat both gram-positive and gram-negative 
bacterial infections.2,3 The tetracycline family are bacteriostatic,2 halting the reproduction of 
bacterial cells by inhibiting protein synthesis via binding to the 30s-ribosomal subunit.2-4 In 
addition to their antimicrobial abilities, tetracyclines demonstrate neuroprotective, anti-
inflammatory and immunosuppressive properties,2,5,6 allowing this class to treat other conditions 
including rosacea and rheumatoid arthritis.2,7 Minocycline, along with doxycycline, is a second-
generation semi-synthetic tetracycline1,4,5,8-12 which was developed with improved absorption 
and lipophilicity allowing both oral and intravenous administration.3  
Although minocycline specifically has several advantageous properties over other tetracyclines,2 
it has been documented to have a variety of adverse reactions including nausea, vomiting, 
dizziness,1,2,8-10 hepatotoxicity,1,2,6,9-11,13 vasculitis,4,6 organ dysfunction1,8 (including 
polyarthritis, nephritis, pneumonitis, and pancreatitis), pseudotumor cerebri5,9,10 and medication-
induced lupus.2,4,5,8-11 An uncommon yet unfortunate adverse reaction to minocycline, however, 
is pigmentation related and tends to occur more often when compared to other tetracyclines.2,7 In 
this case, these visible risks of minocycline are more closely examined.  
Case Presentation  
At a routine follow up visit for hypertension and hyperlipidemia, a 70-year-old white female 
with a history of ocular rosacea was noted to have “tanned skin.” She denied excess sun 
exposure and a workup for causes of increased skin pigmentation was unfruitful for any 
metabolic source. Her medications at that time included doxycycline 100mg daily that had been 
prescribed for ocular rosacea by her ophthalmologist consistently for 4 years. She was informed 
of the suspected source of the skin changes and advised to stop doxycycline and discuss 
alternative treatment with the prescribing physician.  
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Three years later, she presented with a six-month history of diarrhea and fatigue. Increased 
pigmentation on her forehead and cheeks bilaterally was also noted. Physical examination was 
unremarkable except for generalized hyperpigmentation and blue/black discoloration over the 
maxillary and temporal areas of her face (Picture 1). The medication review revealed that she 
had been started on minocycline treatment for ocular rosacea after her doxycycline was 
discontinued. Evaluation for causes of hyperpigmentation, fatigue, and diarrhea was again 
negative. She was advised to stop the minocycline. On repeat examinations, not only did her 
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Picture 1: Demonstrates the generalized brownish pigmentation to the face, neck, and hand of a 
Type III reaction (case-patient). 
Discussion 
Pharmacokinetics 
Compared to the older first-generation tetracyclines, minocycline’s pharmacokinetic profile 
shows some clear advances. Minocycline (7-dimethylamino-6-demethyl-6-deoxytetracycline) 
differs structurally from tetracycline by the addition of a dimethylamino group at the seventh 
carbon.6 Due to its lipid solubility, its absorption rate between the stomach and jejunum is 95-
100% in all populations, including the elderly, regardless of food intake.2-4,7,10 Concomitant iron 
and antacids containing calcium and magnesium, however, can reduce the absorption.3 Its 
lipophilic nature not only promotes wide distribution in tissues, allowing crossing of the blood-
brain barrier,2,3,7,14 but also reduces resistance.10,15 Three quarters of the medication is protein 
bound.3,7 Maximal dose is reached within 2 hours, with a dose-dependent variability and a half-
life of 12-18 hours.2,3,10,12,15,16 The renal clearance of minocycline is 1.2-2.2 ml/min with 5-12% 
of the drug excreted in the urine and 20-35% eliminated in feces.3 Minocycline produces six 
metabolites with antimicrobial activity furthering its effectiveness.3 This unusual metabolism 
may also contribute to its unique adverse effects, such as abnormal pigmentation, which is 
observed in patients with long term minocycline use.6 
Pigmentary Changes in Minocycline Use 
Minocycline is routinely prescribed as 100 mg daily with the highest dose recommendations by 
the Federal Drug Administration being 200 mg daily to avoid side effects.2,9 Hyperpigmentation 
is the most common side effect from the cumulative administration of minocycline7 and is often 
blamed on its rapid absorption and longer half-life.15 The classic pigmentation presentation 
patterns have been classified into four separate types (Table 1). Type 1 demonstrates a blue-
black pigmentation primarily around areas of previous scarring or inflammation.7,9,12,15 Under 
microscopy, perivascular macrophages laden with granules of pigment chelated with iron, 
hemosiderin, and ferritin are seen.7,15 The pigmentation does not correspond to either duration or 
cumulative dose of minocycline.9,15 Therefore, it may be more rapidly seen but also resolves with 
discontinuation of the medication.7,15 The Type 2 variant is diffuse, presenting as blue, black or 
gray discoloration on the shins, arms, and ankles.7,12,15 It is dose-dependent, associated with a 
lifetime accumulation of 70g-100g of minocycline. It takes longer to present and months to 
resolve after discontinuation of the medication.7,12,14,15 Minocycline oxidative degradation 
products chelated with iron can be observed microscopically as a membrane-bound pigment 
collection in the dermis and subcutis or free in collagen fibers.7,15 Laser treatment can speed 
resolution by fragmenting both intracellular and extracellular pigments to aid drainage by the 
lymphatic system. Only mild desquamation and transient purpura are seen as adverse events of 
this treatment.12 Type 3 reactions are unique compared to Types 1 and 2 because microscopically 
the pigmentation is composed of minocycline-melanin complexes.7,15 This presents as a 
generalized brown coloration at sun-exposed sites.7,12,15 This too is a cumulative effect,7,9,14,15 as 
is type 2, but it is more likely to be permanent with less efficacy of laser treatments.7,12 Type 4 
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pigmentation is similar to Type 1 but has been described as an independent phenotype, appearing 
as either a bluish pigmentation of the lips or blue-black pigmented scarring on the posterior 
thorax. Microscopically it differs slightly in that the pigment seems post-inflammatory from a 
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Table 1: Comparison of the different types of cutaneous pigmentary reactions to minocycline. 
From the large cumulative dose, generalized brownish coloration and lack of significant 









Other Dermatologic Manifestations of Minocycline 
Adverse dermatologic and pigmentary reactions to minocycline can occur outside of these four 
classic types (Table 2). Multiple cases of hyperpigmentation occurring at the skin,7,10,14 nail 
beds,7 teeth,7,9 bones,7,9,14 cartilage,7,9 mucus membranes,7,9 thyroid,7,9 tongue,7,10,14 sclera,7,9 
cardiac valves9, and breast milk7 have been documented. There are multiple theories pertaining to 
the cause of hyperpigmentation. These include the formation of insoluble salts from minocycline 
degradation, siderosis, accumulation of black degradation products at different tissue locations, 
melanocyte enhancement, and derivatives of minocycline forming complexes chelated to iron, 
melanin, and calcium.9,10,12,15 Other non-pigmentary dermatologic changes can occur from 
minocycline exposure, including urticaria caused by vasoactive amines released from mast cells 
during a hypersensitivity reaction,1,2,5,11 subcutaneous nodules and livedo reticularis from 
polyarteritis nodosa,4,6,11 vasculitis,6,11 denudation and hemorrhagic changes of Stevens-Johnson 
Syndrome,4 as well as erythema in sun-exposed areas from photosensitivity rashes.4 
 
Reaction Site Mechanism of Disease and/or Clinical Presentation 
Bone Occurs as a result of accumulated deposits chelated with iron, calcium 
and hemosiderin.  
Breast Milk  Lipophilic nature facilitates the accumulation of macrophages with 
iron complexes. 
Cartilage Occurs as a result of accumulated deposits chelated with iron, 
calcium, and hemosiderin.  
Eyes Blue-Gray discoloration occurs in the conjunctiva and sclera from a 
Type III-like hyperpigmentation mechanism.  
Mucous Membranes Rare. Only occurs with minocycline. Areas of trauma demonstrate 
complexes with iron or calcium.  
Nails  Graying of the proximal nailbed by a Type III-like hyperpigmentation 
pathology. Less common than skin manifestations.  
Teeth Occurs 6% of the time. Permanent blue-gray discoloration. Enamel is 
etched.  
Thyroid Gland Oxidation by thyroid peroxidase as a result of long-term use.  
Table 2: Catalogue of the potential pigmentary manifestations of minocycline. 
Patient 
Interestingly, patients being treated for rosacea have a higher chance of abnormal pigmentation 
than those being treated for routine acne,7,15 as they are usually older and have received higher 
cumulative doses of minocycline than the younger patients treated for acne vulgaris.7 In this 
case, the patient was treated for rosacea first with doxycycline, followed by minocycline with an 
estimated cumulative dose of over 100 grams of minocycline in the three years after the 
tetracycline was discontinued. Not surprisingly, she developed a Type III reaction from the 
minocycline cumulative dose. Also, not surprisingly, she has shown very little improvement after 
discontinuation. 
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The frequency with which Minocycline is used casts it in a light that makes it seem benign. 
Whether it is pigment deposition or stimulating a dermatologic process, its effect on the patient 
can be significant and permanent. Remembering the possible ramifications will allow physicians 
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